Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2002

View Archived Issues

Verapamil is effective in the treatment of Peyronie's disease

ABI-007, a new cremophor-free nanoparticle formulation of paclitaxel

Kansas State University researchers identify nucleoside transport inhibitor TT-24

IL-10 gene therapy prevents recurrence of autoimmune diabetes after islet transplantation

CD45RB MAb prolongs allograft survival in mice

Bimosiamose prolongs rat kidney allograft survival by reducing intragraft cytokine production

Inhibition of COX-2 with NS-398 prolongs allogeneic cardiac graft survival

Takeda presents SAR studies for TAK-013 and TAK-810

UCB-35440 discussed at recent ACS meeting

Cyclic beta-amino acids with VLA-4 antagonist activity presented at ACS

Milnacipran to be studied in depressed mood associated with chronic pain conditions

Pfizer submits IND for bone growth product

Sankyo files supplemental NDA for Benicar HCT

Lantus launch in U.K.

P-54 may reduce steroid dependency in patients with mild inflammatory bowel disease

Xigris approved in E.U.

Orion files NDA for triple combination therapy for Parkinson's disease

A-317920 shows potential for Alzheimer's disease and ADHD

Bayer claims compounds with antitumor activity

Orexin receptor antagonists described by Actelion

Antifungal compounds that inhibit CIV1 activity

Telomerase-inhibiting compounds described by Geron and Kyowa Hakko

New mGLUR1 antagonists claimed by Roche for neurological disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...